Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
LRMR
LRMR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LRMR News
Investigation Launched into Larimar Therapeutics for Possible Securities Fraud
20h ago
Globenewswire
Larimar Therapeutics Regulatory Progress Highlights Value Potential
5d ago
stocktwits
Pomerantz LLP Investigates Securities Fraud Claims Against Larimar Therapeutics
6d ago
PRnewswire
Larimar Submits Biologics License Application for Nomlabofusp
Jun 29 2026
NASDAQ.COM
Larimar Submits Biologics License Application for Friedreich's Ataxia Treatment
Jun 29 2026
stocktwits
Larimar Submits Biologics License Application for Nomlabofusp
Jun 29 2026
Newsfilter
Larimar Therapeutics to Host Investor Event on Nomlabofusp Program
Jun 27 2026
NASDAQ.COM
Larimar Therapeutics to Host Investor Event on Clinical Updates
Jun 26 2026
Newsfilter
Biotech Companies See Significant Stock Gains
Jun 10 2026
NASDAQ.COM
Wall Street's Latest Rating Changes Overview
May 27 2026
CNBC
Larimar Therapeutics Q1 Earnings Beat Expectations
May 14 2026
seekingalpha
Larimar Therapeutics Reports Q4 Loss Exceeding Expectations
Mar 19 2026
seekingalpha
Larimar Therapeutics Prices Upsized Public Offering of 20 Million Shares
Feb 26 2026
NASDAQ.COM
Marriott Vacations Reports Strong Q4, Shares Surge
Feb 26 2026
Benzinga
Larimar Therapeutics Prices Upsized Public Offering of 20M Shares at $5.00 Each
Feb 26 2026
seekingalpha
Wall Street Opens Cautiously Amid China Market Concerns
Feb 26 2026
stocktwits
Show More News
